Welcome to our dedicated page for Trevena news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena stock.
Trevena, Inc. reports developments as a biopharmaceutical company developing and commercializing medicines for central nervous system disorders. Its updates center on OLINVYK® (oliceridine) injection, a U.S.-approved intravenous opioid analgesic for acute pain in adults when alternatives are inadequate, and investigational CNS programs including TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for acute migraine, and TRV734 for maintenance treatment of opioid use disorder.
Recurring company news also covers financial results, cash resources, preclinical and formulation-study updates for TRV045, royalty-based financing arrangements tied to ex-U.S. OLINVYK economics, liability reductions, reverse stock splits, and trading-status changes following Nasdaq delisting and movement to OTC markets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.